173 related articles for article (PubMed ID: 36831276)
1. FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia.
Figurek A; Rroji M; Spasovski G
Cells; 2023 Feb; 12(4):. PubMed ID: 36831276
[TBL] [Abstract][Full Text] [Related]
2. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 is pumping iron: C-terminal-fibroblast growth factor 23 cleaved peptide and its function in iron metabolism.
Courbon G; David V
Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):368-374. PubMed ID: 38661434
[TBL] [Abstract][Full Text] [Related]
4. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
[TBL] [Abstract][Full Text] [Related]
5. Associations between anemia and FGF23 in the CKiD study.
Thomas E; Klomhaus AM; Laster ML; Furth SL; Warady BA; Salusky IB; Hanudel MR
Pediatr Nephrol; 2024 Mar; 39(3):837-847. PubMed ID: 37752381
[TBL] [Abstract][Full Text] [Related]
6. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
[TBL] [Abstract][Full Text] [Related]
7. High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes.
Verkaik M; Oranje M; Abdurrachim D; Goebel M; Gam Z; Prompers JJ; Helmes M; Ter Wee PM; van der Velden J; Kuster DW; Vervloet MG; Eringa EC;
Physiol Rep; 2018 Apr; 6(7):e13591. PubMed ID: 29611320
[TBL] [Abstract][Full Text] [Related]
8. Ironing out the cross talk between FGF23 and inflammation.
David V; Francis C; Babitt JL
Am J Physiol Renal Physiol; 2017 Jan; 312(1):F1-F8. PubMed ID: 27582104
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.
Agoro R; Montagna A; Goetz R; Aligbe O; Singh G; Coe LM; Mohammadi M; Rivella S; Sitara D
FASEB J; 2018 Jul; 32(7):3752-3764. PubMed ID: 29481308
[TBL] [Abstract][Full Text] [Related]
10. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.
Yeung SMH; Bakker SJL; Laverman GD; De Borst MH
Curr Diab Rep; 2020 Aug; 20(10):50. PubMed ID: 32857288
[TBL] [Abstract][Full Text] [Related]
12. In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy.
Williams MJ; Halabi CM; Patel HM; Joseph Z; McCommis K; Weinheimer C; Kovacs A; Lima F; Finck B; Malluche H; Hruska KA
Am J Physiol Renal Physiol; 2024 May; 326(5):F751-F767. PubMed ID: 38385175
[TBL] [Abstract][Full Text] [Related]
13. Lipocalin-2: a novel link between the injured kidney and the bone.
Courbon G; David V
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):312-319. PubMed ID: 35727169
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 23: are we ready to use it in clinical practice?
Bouma-de Krijger A; Vervloet MG
J Nephrol; 2020 Jun; 33(3):509-527. PubMed ID: 32130720
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow sinusoidal endothelial cells are a site of Fgf23 upregulation in a mouse model of iron deficiency anemia.
Li X; Lozovatsky L; Tommasini SM; Fretz J; Finberg KE
Blood Adv; 2023 Sep; 7(17):5156-5171. PubMed ID: 37417950
[TBL] [Abstract][Full Text] [Related]
16. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.
Charytan DM; Fishbane S; Malyszko J; McCullough PA; Goldsmith D
Am J Kidney Dis; 2015 Aug; 66(2):196-205. PubMed ID: 25727384
[TBL] [Abstract][Full Text] [Related]
17. Kidney clearance of fibroblast growth factor-23 in humans.
Sharma S; Ix JH
Curr Opin Nephrol Hypertens; 2023 Jul; 32(4):330-334. PubMed ID: 37195253
[TBL] [Abstract][Full Text] [Related]
18. Extracellular sodium regulates fibroblast growth factor 23 (FGF23) formation.
Radvanyi Z; Yoo EJ; Kandasamy P; Salas-Bastos A; Monnerat S; Refardt J; Christ-Crain M; Hayashi H; Kondo Y; Jantsch J; Rubio-Aliaga I; Sommer L; Wagner CA; Hediger MA; Kwon HM; Loffing J; Pathare G
J Biol Chem; 2024 Jan; 300(1):105480. PubMed ID: 37992803
[TBL] [Abstract][Full Text] [Related]
19. Continued Search for Therapies to Favorably Modify Phosphate and FGF23 Levels in CKD.
Mehta R; Isakova T
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1911-1913. PubMed ID: 29074819
[No Abstract] [Full Text] [Related]
20. Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease.
Fuchs MA; Burke EJ; Latic N; Murray S; Li H; Sparks M; Abraham D; Zhang H; Rosenberg P; Hänzelmann S; Hausmann F; Huber T; Erben R; Fisher-Wellman K; Bursac N; Wolf M; Grabner A
Res Sq; 2023 Dec; ():. PubMed ID: 38196615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
